A consensus viewpoint on the role of direct factor Xa inhibitors in the management of cancer-associated venous thromboembolism in the UK.

Alexander T CohenGary BensonCharlotte A BradburySatarupa ChoudhuriNathan Hutchinson JonesAnthony MaraveyasBalaji VenugopalAnnie M YoungChris ChapmanShauna McIntyreDanny BurneyKevin G PollockAngharad R MorganPeter D GabbRaza Alikhan

Published in: Current medical research and opinion (2023)

Anticoagulant therapy for cancer-associated VTE patients should be carefully selected with consideration given to the relative benefits of specific drugs when individualizing care. Direct factor Xa inhibitors are typically the treatment of choice for preventing VTE recurrence in non-cancer patients and should also be considered as such for cancer-associated VTE in most situations.

Keyphrases

venous thromboembolism
direct oral anticoagulants
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
palliative care
prognostic factors
peritoneal dialysis
patient reported outcomes
free survival
health insurance
affordable care act
smoking cessation